ライフサイエンスコーパス: cryoprecipitate

1 2%) received plasma, and 394 (5.3%) received cryoprecipitate.

2 A total of 541 patients (27.8%) received cryoprecipitate.

3 Plasma from 4 patients with type I VWD was cryoprecipitated.

4 Fibrinogen concentrate (4 g per dose) or cryoprecipitate (10 units per dose) randomized (1:1) up

5 Fibrinogen concentrate (4 g; n = 415) or cryoprecipitate (10 units; n = 412) for each ordered dos

6 mortality was lowest in the tranexamic acid/cryoprecipitate (11.6%) and tranexamic acid (18.2%) grou

7 examic acid (18.2%) groups compared with the cryoprecipitate (21.4%) and no tranexamic acid/cryopreci

8 yoprecipitate (21.4%) and no tranexamic acid/cryoprecipitate (23.6%) groups.

9 plasma, 9.6 +/- 4.9 U vs. 4.9 +/- 3.6 U; and cryoprecipitate, 4.3 +/- 3.6 U vs. 2.2 +/- 3.5 U; p < 0.

10 ce), or cryoprecipitate, in which 3 pools of cryoprecipitate (6-g fibrinogen equivalent) were to be a

11 rozen plasma (4.8 versus 3.1 U, P<0.03), and cryoprecipitate (9.9 versus 5.4 U, P<0.002) than patient

12 nd more aggressive use of plasma, platelets, cryoprecipitate and coagulation factor isolates, decreas

13 Cryoprecipitate and selected factor VIII concentrates ar

14 complex with fibrin by gel chromatography of cryoprecipitates and then separated from the fibrin eith

15 g 16569 U of RBCs, 13933 U of FFP, 5228 U of cryoprecipitate, and 22635 U of platelets.

16 anti-Fas antibody, normal plasma depleted of cryoprecipitate, and low concentrations (< or = 0.1 micr

17 y use of platelets, fresh frozen plasma, and cryoprecipitate; and adjusting for country produced resu

18 The benefit of cryoprecipitate appeared to persist for 7 days only in t

19 en-carrying capacity; platelets, plasma, and cryoprecipitate are intended to facilitate hemostasis th

20 were treated with fibrinogen concentrates or cryoprecipitates as prophylaxis, 18.1% (n = 37) received

21 ned with a multiple myeloma serum containing cryoprecipitates, but multiple myeloma sera without cryo

22 The influence of cryoprecipitate (CP) on liver histology and peripheral t

23 on develop detectable serum cryoglobulins or cryoprecipitates (CP), although most do not show clinica

24 otease is present in fresh-frozen plasma, in cryoprecipitate-depleted plasma (cryosupernatant), and i

25 The combined tranexamic acid and cryoprecipitate effect vs. neither in a synergy model ha

26 Assay of cryoprecipitate from the plasma of affected mice failed

27 of thrombotic events in the standard care vs cryoprecipitate group (12.9% vs 12.7%).

28 % in the standard care group vs 25.3% in the cryoprecipitate group (odds ratio, 0.96 [95% CI, 0.75-1.

29 and 17.0 (95% CI, 15.6 to 18.6) units in the cryoprecipitate group (ratio, 0.96 [1-sided 97.5% CI, -i

30 ligible patients, 799 were randomized to the cryoprecipitate group and 805 to the standard care group

31 140 [USD $849]-CAD $5000 [USD $3723]) in the cryoprecipitate group.

32 D $19 495]-CAD $70 380 [USD $52 409]) in the cryoprecipitate group.

33 centrate group and 35 patients (9.6%) in the cryoprecipitate group.

34 nsity score weighting, patients who received cryoprecipitate had a significantly lower 24-hour mortal

35 phritis showed better correlation with serum cryoprecipitate immunofixation than conventional immunof

36 Thus, the cryoprecipitate in C57BL/6 mice consisted of the IgG3 cr

37 entrate is cost-effective when compared with cryoprecipitate in most bleeding adult patients who unde

38 expansion (P = .01), highlighting a role for cryoprecipitate in reversing rtPA coagulopathy.

39 arly, patients given aprotinin received more cryoprecipitate in the intensive care unit (7.3 versus 3

40 st massive transfusion protocols incorporate cryoprecipitate in the treatment of hemorrhaging injured

41 d-derived platelets in plasma, and prepooled cryoprecipitate in varying pool sizes.

42 ower use of blood components (FFP, PLTs, and cryoprecipitate) in the TEG group compared with the SOC

43 tocol (reviewed for guideline adherence), or cryoprecipitate, in which 3 pools of cryoprecipitate (6-

44 other experienced recurrent thrombosis after cryoprecipitate infusions following surgery.

45 ailable therapies-fibrinogen concentrate and cryoprecipitate-is unknown.

46 Cryoprecipitate may independently add to the survival be

47 an [SD], 23.0 [19.2]) and no tranexamic acid/cryoprecipitate (mean [SD], 21.2 [18.5]) (P < .001) grou

48 (mean [SD], 28.3 [15.7]) and tranexamic acid/cryoprecipitate (mean [SD], 26 [14.9]) groups compared w

49 Injury severity scores were highest in the cryoprecipitate (mean [SD], 28.3 [15.7]) and tranexamic

50 following groups: tranexamic acid (n = 148), cryoprecipitate (n = 168), tranexamic acid/cryoprecipita

51 , cryoprecipitate (n = 168), tranexamic acid/cryoprecipitate (n = 258), and no tranexamic acid/cryopr

52 recipitate (n = 258), and no tranexamic acid/cryoprecipitate (n = 758).

53 on extracorporeal membrane oxygenation, and cryoprecipitate on 14%.

54 mbrane oxygenation, plasma on one third, and cryoprecipitate on one sixth of the days.

55 elines recommend fibrinogen replacement with cryoprecipitate or fibrinogen concentrate.

56 Fibrinogen therapy can be administered with cryoprecipitate or fibrinogen concentrates, and clinical

57 onvirally inactivated factor concentrates or cryoprecipitates prepared from local blood donors was co

58 cipitates, but multiple myeloma sera without cryoprecipitates presented no problem in the EIA system.

59 egativity to HHV-6 (P=0.034), intraoperative cryoprecipitate requirements greater than the 75th perce

60 plasma (RR, 0.37; 95% CI, 0.21 to 0.64), and cryoprecipitate (RR:0.06; 95% CI, 0.02 to 0.22) were low

61 he addition of early and empirical high-dose cryoprecipitate to standard care did not improve all cau

62 Daily cryoprecipitate transfusion dose was independently assoc

63 tively), and increased red cell, plasma, and cryoprecipitate transfusion.

64 as well as risk of packed red blood cell and cryoprecipitate transfusions after coronary artery bypas

65 Management is fibrinogen replacement with cryoprecipitate transfusions or fibrinogen concentrate,

66 In many countries, only plasma or cryoprecipitate treatments are available, but these carr

67 ts (3 vs. 1.6, p =0.0004), and the number of cryoprecipitate units (2.4 vs. 1.2, p =.04) transfused a

68 Moreover, cryoprecipitate use was associated with a significantly

69 Cryoprecipitate use within the first 4 hours of emergenc

70 onents (fresh frozen plasma [FFP], PLTs, and cryoprecipitate) versus 87.2% in the SOC group (P < 0.00

71 ty to proteolysis of the VWF in the VWF-rich cryoprecipitate was assessed by incubation with a normal

72 In this cohort study, early use of cryoprecipitate was associated with lower 24-hour mortal

73 n requirements of packed red blood cells and cryoprecipitate was higher in the patients with severe m

74 tal net benefit of fibrinogen concentrate vs cryoprecipitate was positive willingness-to-pay, respect

75 Tranexamic acid and cryoprecipitate were independently associated with a sim

76 tients, 735 (372 fibrinogen concentrate, 363 cryoprecipitate) were treated and included in the primar

77 icted transfusion of fresh frozen plasma and cryoprecipitate with modest to high overall accuracy.

78 ss, fibrinogen concentrate is noninferior to cryoprecipitate with regard to number of blood component